| Investigator |
Title |
Sponsor |
ID |
Dates |
Amount |
| Craig Andrew Erickson, MD |
Using Longitudinal Data to Characterize the Natural History of Fragile X Syndrome (FXS) to Improve Services and Outcomes |
Ctr for Disease Control and Prevention |
U01 DD001185 |
09/01/2019 - 08/31/2020 |
$99,998 |
| Craig Andrew Erickson, MD |
Use of fNIRS to measure treatment response in young children with FXS. |
FRAXA Research Foundation |
FRAXA-Erickson, Crai |
07/01/2019 - 06/30/2020 |
$45,000 |
| Craig Andrew Erickson, MD |
Mechanisms of Neocortical and sensory Hyperexcitability in Fragile X Syndrome |
University of Cincinnati (National Institutes of Health) |
012352-002 |
06/01/2019 - 05/31/2020 |
$261,185 |
| Craig Andrew Erickson MD |
Pilot study of Minocycline |
Autism Speaks Grant Administration |
11259 |
08/24/2019 - 06/30/2020 |
$48,634 |
| Drew Barzman, MD |
A Multi-Site Study to Compare the Outcomes of Psychiatric Treatment of Suicidal Adolescents in Different Treatment Settings |
Patient-Centered Outcome Research Inst. |
PCS-2018C1-11111 |
06/01/2019 - 05/31/2020 |
$1,414,044 |
| Michael T Sorter, MD |
Mobility: Improving Patient-Centered Outcomes Among Overweight and Obese Youth with Bipolar Spectrum Disorders Treated with Second-Generation Antipsychotics |
University of Cincinnati (Patient-Centered Outcome Research Inst.) |
Sorter_UC_PCORI |
09/01/2019 - 08/31/2020 |
$250,207 |
| Current Year Direct |
$2,119,068 |
